Abhishek Jain is recorded as CFO at Neogenomics Inc (NEO) and CFO at CareDx, Inc. (CDNA). The newest filing on record that lists Abhishek Jain as CFO at CareDx, Inc. (CDNA) is dated April 27, 2026. Neogenomics Inc reported in an 8-K filed January 12, 2026 that Abhishek Jain was appointed Chief Financial Officer, effective March 2, 2026. CareDx, Inc. reported in an 8-K filed August 6, 2025 that Abhishek Jain retired as Chief Financial Officer, effective August 6, 2025. CareDx, Inc. reported in an 8-K filed September 7, 2022 that Abhishek Jain was appointed Chief Financial Officer, effective September 7, 2022. The proxy statement of CareDx, Inc. reports total compensation of $2,637,934 for Abhishek Jain in fiscal 2025, including a base salary of $282,100. Disclosed compensation is on record for 3 fiscal years. Abhishek Jain has spoken on 17 earnings calls and 2 other investor events across 2 companies, most recently for Neogenomics Inc on October 28, 2026. Those appearances were for CareDx, Inc. (CDNA) and Neogenomics Inc (NEO). CareDx, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at CareDx, Inc. includes Alexander L. Johnson (CEO), John W. Hanna (CEO and Board Member), Michael D. Goldberg (Chairman and Board Member) and 7 others.
“Mr. Jain is expected to assume the role of Chief Financial Officer on March 2, 2026, when Mr. Sherman transitions to the role of Executive Vice President, Finance.”
Neogenomics Inc Form 8-K, filed January 12, 2026
· Read the filing
“On August 6, 2025, the Company announced Abhishek Jain retired from his position as the Company's Chief Financial Officer, pursuant to which Mr. Jain's employment will conclude effective as of August 6, 2025 (the "Separation Date").”
CareDx, Inc. Form 8-K, filed August 6, 2025
· Read the filing
Abhishek Jain on recent calls
“In my remarks today, I will discuss our third quarter financial reserves and our updated 2026 guidance. We reported total revenue of $209 million, up 11% year-over-year.”
“So on the NGS revenue growth, first like 26% growth is what we put together in the first half of the year. We have called out the volume growth has been in the mid-team and the remaining came from the RCM initiatives and the RCM growth.”
“Before we begin, I would like to introduce Andrew Brackman, who recently joined NeoGenomics as our new Vice President of Investor Relations. Andrew spent nearly a decade in cell-side equity research covering the diagnostic sector.”
“I think it's the same, what Tony basically just kind of elaborated. My top priority is to basically make sure that we continue to fuel the revenue growth. That stays the most important one.”
“In my remarks today, I will discuss our first quarter financial results and revised 2026 guidance. We reported total revenue of $186.7 million, up 11% year-over-year, driven by clinical revenue of $171.2 million, which blew a strong 14%.”
